Journal Article

Maternofetal consequences of Coxiella burnetii infection in pregnancy: a case series of two outbreaks

Baier, Michael, Boden, Katharina, Henning, Klaus, Seidel, Thomas, Straube, Eberhard, Brueckmann, Andreas, Hermann, Beate, Junghanss, Thomas, Theegarten, Dirk, Wagner-Wiening, Christiane

2012

Overview

Background A high complication rate of Q fever in pregnancy is described on the basis of a limited number of cases. All pregnant women with proven Q fever regardless of clinical symptoms should therefore receive long-term cotrimoxazole therapy. But cotrimoxazole as a folic acid antagonist may cause harm to the fetus. We therefore investigated the Q fever outbreaks, Soest in 2003 and Jena in 2005, to determine the maternofetal consequences of Coxiella burnetii infection contracted during pregnancy. Methods Different outbreak investigation strategies were employed at the two sides. Antibody screening was performed with an indirect immunofluorescence test. Medical history and clinical data were obtained and serological follow up performed at delivery. Available placental tissue, amniotic fluid and colostrum/milk were further investigated by polymerase chain reaction and by culture. Results 11 pregnant women from Soest (screening rate: 49%) and 82 pregnant women from Jena (screening rate: 27%) participated in the outbreak investigation. 11 pregnant women with an acute C. burnetii infection were diagnosed. Three women had symptomatic disease. Three women, who were infected in the first trimester, were put on long-term therapy. The remaining women received cotrimoxazole to a lesser extent (n=3), were treated with macrolides for three weeks (n=1) or after delivery (n=1), were given no treatment at all (n=2) or received antibiotics ineffective for Q fever (n=1). One woman and her foetus died of an underlying disease not related to Q fever. One woman delivered prematurely (35 th week) and one child was born with syndactyly. We found no obvious association between C. burnetii infection and negative pregnancy outcome. Conclusions Our data do not support the general recommendation of long-term cotrimoxazole treatment for Q fever infection in pregnancy. Pregnant women with symptomatic C. burnetii infections and with chronic Q fever should be treated. The risk-benefit ratio of treatment in these patients, however, remains uncertain. If cotrimoxazole is administered, folinic acid has to be added.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Analysis / Anti-Bacterial Agents - administration & dosage / Anti-Bacterial Agents - adverse effects / Antibiotics / Antibodies / Antibodies, Bacterial - blood / Colostrum - microbiology / Coxiella burnetii / Coxiella burnetii - genetics / Coxiella burnetii - immunology / Coxiella burnetii - isolation & purification / Disease Outbreaks / Female / Fluorescent Antibody Technique, Indirect / Folic acid / Health aspects / Health care / Health risk assessment / Humans / Infant, Newborn / Infectious Diseases / Internal Medicine / Medical Microbiology / Medicine / Medicine & Public Health / Milk, Human - microbiology / Outbreaks / Parasitology / Patient outcomes / Placenta - microbiology / Polymerase Chain Reaction / Pregnancy / Pregnancy Complications, Infectious - drug therapy / Pregnant women / Q fever / Q Fever - complications / Q Fever - drug therapy / Q Fever - epidemiology / Research Article / Respiratory distress syndrome / Trimethoprim, Sulfamethoxazole Drug Combination - administration & dosage / Trimethoprim, Sulfamethoxazole Drug Combination - adverse effects / Tropical Medicine / Viral antibodies / Womens health